Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2021 Filed Feb 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,499 | $61.47 | $215,083.53 |
DisclosureSEC source: 0001209191-21-012906 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,501 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.84 to 61.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-012906 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 19, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 416 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001209191-21-017308 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Underlying: Common Stock · 416 shares Expires 2027-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 19, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 416 | $61.20 | $25,459.20 |
DisclosureSEC source: 0001209191-21-017308 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| February 19, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 416 | $6.27 | $2,608.32 |
DisclosureSEC source: 0001209191-21-017308 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,108 | $61.20 | $557,409.60 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.05 to 61.34, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,892 | $60.49 | $356,407.08 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,108 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.15 to 60.90, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,799 | $62.28 | $610,281.72 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.02 to 62.92, inclusive. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,201 | $61.63 | $320,537.63 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,799 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.16 to 61.955, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-012596 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:26 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-011065 · doc4.xml · derivative · entry 5 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 6,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:26 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 6,000 | $65.08 | $390,480.00 |
DisclosureSEC source: 0001209191-21-011065 · doc4.xml · nonDerivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.49 to 65.45, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 01:26 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 6,000 | $7.80 | $46,800.00 |
DisclosureSEC source: 0001209191-21-011065 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:01 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-011548 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:01 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 9,256 | $65.29 | $604,324.24 |
DisclosureSEC source: 0001209191-21-011548 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.00 to 65.67, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:01 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 2,100 | $64.56 | $135,576.00 |
DisclosureSEC source: 0001209191-21-011548 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,556 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.00 to 64.98, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:01 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 4,894 | $63.43 | $310,426.42 |
DisclosureSEC source: 0001209191-21-011548 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,656 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.00 to 63.995, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:01 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 16,250 | $31.71 | $515,287.50 |
DisclosureSEC source: 0001209191-21-011548 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-011555 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 2,000 | $65.45 | $130,900.00 |
DisclosureSEC source: 0001209191-21-011555 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-21-011555 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-011554 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 13,301 | $65.31 | $868,688.31 |
DisclosureSEC source: 0001209191-21-011554 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.00 to 65.67, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 1,699 | $64.78 | $110,061.22 |
DisclosureSEC source: 0001209191-21-011554 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.34 to 64.99, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-011554 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-011553 · doc4.xml · derivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 9,528 | $65.29 | $622,083.12 |
DisclosureSEC source: 0001209191-21-011553 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.00 to 65.67, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 1,700 | $64.59 | $109,803.00 |
DisclosureSEC source: 0001209191-21-011553 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,528 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.03 to 64.98, inclusive. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 5,022 | $63.42 | $318,495.24 |
DisclosureSEC source: 0001209191-21-011553 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,228 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.00 to 63.97, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:01 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 16,250 | $31.71 | $515,287.50 |
DisclosureSEC source: 0001209191-21-011553 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-011547 · doc4.xml · derivative · entry 5 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 2,000 | $65.45 | $130,900.00 |
DisclosureSEC source: 0001209191-21-011547 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionCommon Stock | 2,000 | $0.45 | $900.00 |
DisclosureSEC source: 0001209191-21-011547 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:40 UTC |
GOEL DAVID E.Director
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0000902664-21-001476 · ownership.xml · derivative · entry 2 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-15 F2 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:40 UTC |
GOEL DAVID E.Director
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-21-001476 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 01:26 UTC |
GRIFFIN MICHELLE RENEEDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011065 · doc4.xml · derivative · entry 4 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F3 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 01:26 UTC |
GRIFFIN MICHELLE RENEEDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011065 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:01 UTC |
DOBMEIER ERICDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011549 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:01 UTC |
DOBMEIER ERICDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011549 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
NEUPERT PETER MDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011551 · doc4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
NEUPERT PETER MDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011551 · doc4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
HERSHBERG ROBERTDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011547 · doc4.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F2 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
HERSHBERG ROBERTDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011547 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
Conroy Kevin TDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011550 · doc4.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
Conroy Kevin TDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011550 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
Pellini Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0001209191-21-011546 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 01:00 UTC |
Pellini Michael JDirector
|
GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011546 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.